Abstract:Introduction: Ki67 value and its variation before and after neoadjuvant chemotherapy are commonly tested in relation to breast cancer patient prognosis. This study aims to quantify the extent of changes in Ki67 proliferation pre- and post-neoadjuvant chemotherapy, confirm an optimal cut-off point, and evaluate its potential value for predicting survival outcomes in patients with different molecular subtypes of breast cancer. Methods: This retrospective real-world study recruited 828 patients at the Department of Breast Surgery of the First Affiliated Hospital of China Medical University and the Cancer Hospital of China Medical University from Jan 2014 to Nov 2020. Patient demographic features and disease pathology characteristics were recorded, and biomarkers were verified through immunohistochemistry. Various statistical methods were used to validate the relationships between different characteristics and survival outcomes irrespective of disease-free and overall survival. Results: Among 828 patients, statistically significant effects between pathological complete response and survival outcome were found in both HER2-enriched and triple-negative breast cancer ( p < 0.05) but not in Luminal breast cancer ( p > 0.05). Evident decrease of Ki67 was confirmed after neoadjuvant chemotherapy. To quantify the extent of Ki67 changes between pre- and post-NAC timepoints, we adopted a computational equation termed ΔKi67% for research. We found the optimal cut-off value to be “ ΔKi67% = −63%” via the operating characteristic curve, defining ΔKi67% ≤ −63% as positive status and ΔKi67% > −63% as negative status. Patients with positive ΔKi67% status were 37.1% of the entire cohort. Additionally, 4.7, 39.9, 34.5 and 39.6% of patients with Luminal A, Luminal B, HER2-enriched and triple negative breast cancer were also validated with positive ΔKi67% status. The statistically significant differences between ΔKi67% status and prognostic outcomes were confirmed by univariate and multivariate analysis in Luminal B (univariate and multivariate analysis: p < 0.05) and triple negative breast cancer (univariate and multivariate analysis: p < 0.05). We proved ΔKi67% as a statistically significant independent prognostic factor irrespective of disease-free or overall survival among patients with Luminal B and triple-negative breast cancer. Conclusions: ΔKi67% can aid in predicting patient prognostic outcome, provide a measurement of NAC efficacy, and assist in further clinical decisions, especially for patients with Luminal B breast cancer.

Research of Ki67 as index for further classification of ER + and/or PR + breast cancer

Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis

Ki-67 as a prognostic marker according to breast cancer molecular subtype

Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes

Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses’ Health Study

Quantification of Ki67 Change as a Valid Prognostic Indicator of Luminal B Type Breast Cancer After Neoadjuvant Therapy

Associations and Indications of Ki67 Expression with Clinicopathological Parameters and Molecular Subtypes in Invasive Breast Cancer: A Population-Based Study.

Prognostic Value Of Ki-67 In Breast Cancer Patients With Positive Axillary Lymph Nodes: A Retrospective Cohort Study

Expressions of Progesterone Receptor a and B in Breast Invasive Ductal Carcinoma and Their Clinical Significance

Evaluation of ER-α, ER-β1 and ER-β2 Expression and Correlation with Clinicopathologic Factors in Invasive Luminal Subtype Breast Cancers

Effect of Ki-67 Expression Levels and Histological Grade on Breast Cancer Early Relapse in Patients with Different Immunohistochemical-based Subtypes

The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score

Study on Clinicopathological Classification and Clinical and Pathological Characteristics in Breast Cancer

The clinical significance of Ki-67 as a marker of prognostic value and chemosensitivity prediction in hormone-receptor-positive breast cancer: a meta-analysis of the published literature.

Ki-67 Index Provides Long-Term Survival Information for Early-Stage HER2-Low-Positive Breast Cancer: A Single-Institute Retrospective Analysis.

[Relationship Between Breast Cancer Molecular Subtypes with Clinicopathological Characteristics and Prognosis].

Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study.

Expression of ER,PR, C-erbB-2 and Ki-67 Genes in Breast Cancer and Their Clinical Significance

Combined Use of cyclinD1 and Ki67 for Prognosis of Luminal-Like Breast Cancer Patients

Correlation of biomarker expression and therapeutic efficiency in locally advanced breast cancer after neoadjuvant chemotherapy

Abstract P6-06-57: Progesterone Receptor Status and Ki-67 Index May Predict Early Relapse in Luminal B/HER2 Negative Breast Cancer Patients